Fabry disease

Handbook of Clinical Neurology

Volumn 132, Issue , 2015, Pages 231-248

  Schiffmann, Raphael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiokeratoma; Genetic disease; Heart disease; Sphingolipids; Stroke; X linked

Indexed keywords

ALPHA GALACTOSIDASE; ALPHA-GALACTOSIDASE A, HUMAN;

FABRY DISEASE; FEMALE; GENETICS; HUMAN; MALE; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; HUMANS; MALE; MUTATION;

EID: 84961250610     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62702-5.00017-2     Document Type: Chapter

References (215)

1. Aerts J.M., Groener J.E., Kuiper S., et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008, 105:2812-2817.
2. Aksu H.U., Oner E., Erturk M., et al. Aspirin resistance in patients with impaired renal functions. Kardiol Pol 2013, 72:331-338.
3. Alegra T., Vairo F., de Souza M.V., et al. Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol 2012, 35:947-954.
4. Alroy J., Sabnis S., Kopp J.B. Renal pathology in fabry disease. J Am Soc Nephrol 2002, 13(Suppl 2):S134-S138.
5. Altarescu G., Moore D.F., Pursley R., et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001, 32:1559-1562.
6. Altarescu G., Moore D.F., Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005, 64:2148-2150.
7. Anderson W.A. A case of angiokeratoma. Br J Dermatol 1898, 18:113-117.
8. Anderson L.J., Wyatt K.M., Henley W., et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014, 37:969-978.
9. Attal N., Bouhassira D. Mechanisms of pain in peripheral neuropathy. Acta Neurol Scand Suppl 1999, 173:12-24.
10. Auray-Blais C., Cyr D., Ntwari A., et al. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol Genet Metab 2008, 93:331-340.
11. Banikazemi M., Bultas J., Waldek S., et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007, 146:77-86.
12. Banks D.E., Milutinovic J., Desnick R.J., et al. Silicon nephropathy mimicking Fabry's disease. Am J Nephrol 1983, 3:279-284.
13. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006, 97:1515-1518.
14. Bennett P.C., Silverman S.H., Gill P.S., et al. Peripheral arterial disease and Virchow's triad. Thromb Haemost 2009, 101:1032-1040.
15. Beratis N.G., Varvarigou-Frimas A., Beratis S., et al. Angiokeratoma corporis diffusum in GM1 gangliosidosis, type 1. Clin Genet 1989, 36:59-64.
16. Bichet D.G. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008, 28:245-251.
17. Bishop D.F., Kornreich R., Desnick R.J. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3' untranslated region. Proc Natl Acad Sci U S A 1988, 85:3903-3907.
18. Bodary P.F., Shen Y., Vargas F.B., et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005, 111:629-632.
19. Brady R., Gal A.E., Bradley R.M., et al. Enzymatic defect in Fabry disease: ceramide trihexosidase deficiency. N Engl J Med 1967, 276:1163-1167.
20. Branton M.H., Schiffmann R., Sabnis S.G., et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002, 81:122-138.
21. Buechner S., Moretti M., Burlina A.P., et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008, 79:1249-1254.
22. Burlina A.P., Manara R., Caillaud C., et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 2008, 255:738-744.
23. Cable W.J., Kolodny E.H., Adams R.D. Fabry disease: impaired autonomic function. Neurology 1982, 32:498-502.
24. Cable W.J., McCluer R.H., Kolodny E.H., et al. Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. Neurology 1982, 32:1139-1145.
25. Calzavara-Pinton P.G., Colombi M., Carlino A., et al. Angiokeratoma corporis diffusum and arteriovenous fistulas with dominant transmission in the absence of metabolic disorders. Arch Dermatol 1995, 131:57-62.
26. Case 2-1984 Fabry's disease. N Engl J Med 1984, 310:1607.
27. Chabas A., Coll M.J., Aparicio M., et al. Mild phenotypic expression of alpha-N-acetylgalactosaminidase deficiency in two adult siblings. J Inherit Metab Dis 1994, 17:724-731.
28. Chatterjee S., Gupta P., Pyeritz R.E., et al. Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease. Am J Clin Pathol 1984, 82:24-28.
29. Chien Y.H., Lee N.C., Chiang S.C., et al. Fabry disease: incidence of the common later-onset alpha-galactosidase A IVS4+919G-->A mutation in Taiwanese newborns -superiority of DNA-based to enzyme-based newborn screening for common mutations. Mol Med 2012, 18:780-784.
30. Chimenti C., Pieroni M., Morgante E., et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004, 110:1047-1053.
31. Chung I., Lip G.Y. Virchow's triad revisited: blood constituents. Pathophysiol Haemost Thromb 2003, 33:449-454.
32. Cilmi S.A., Karalius B.J., Choy W., et al. Fabry disease in mice protects against lethal disease caused by Shiga toxin-expressing enterohemorrhagic Escherichia coli. J Infect Dis 2006, 194:1135-1140.
33. Conti G., Sergi B. Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr Suppl 2003, 92:33-37. discussion 27.
34. D'Amico D.J., Kenyon K.R. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981, 4:67-76.
35. De Brabander I., Yperzeele L., Ceuterick-De Groote C., et al. Phenotypical characterization of alpha-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clin Neurol Neurosurg 2013, 115:1088-1093.
36. DeGraba T., Azhar S., Dignat-George F., et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000, 47:229-233.
37. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease 2001, McGraw-Hill, New York. 8th edn. C.R. Scriver, A.L. Beaudet, W.S. Sly (Eds.).
38. Dobrovolny R., Dvorakova L., Ledvinova J., et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl) 2005, 83:647-654.
39. Dobyns W.B. The pattern of inheritance of X-linked traits is not dominant or recessive, just X-linked. Acta Paediatr Suppl 2006, 95:11-15.
40. Donati D., Novario R., Gastaldi L. Natural history and treatment of uremia secondary to Fabry's disease: an European experience. Nephron 1987, 46:353-359.
41. Duncan C. The renal lesion of angiokeratoma corporis diffusum (Fabry's disease): report of three cases including some electron microscopic findings. Pathology 1970, 2:9-14.
42. Dutsch M., Marthol H., Stemper B., et al. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 2002, 19:575-586.
43. El Dib R.P., Nascimento P., Pastores G.M. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2013, 2. CD006663.
44. Elleder M. Sequelae of storage in Fabry disease - pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 2003, 92:46-53. discussion 45.
45. Elliott P., Baker R., Pasquale F., et al. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Heart 2011, 97:1957-1960.
46. Eng C.M., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human alpha-galactosidase A- replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
47. Eng C.M., Fletcher J., Wilcox W.R., et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007, 30:184-192.
48. Eto Y., Ohashi T., Utsunomiya Y., et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005, 28:575-583.
49. Fabry J. Ein Betrag zur Kenntnis der Ppurpura hammarrhagica nodularis. Arch Dermatol Syphilol 1898, 43:187-200.
50. Faggiano A., Pisani A., Milone F., et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab 2006, 91:4319-4325.
51. Fan J.Q., Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. Febs J 2007, 274:4962-4971.
52. Fellgiebel A., Keller I., Marin D., et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 2009, 72:63-68.
53. Fellgiebel A., Keller I., Martus P., et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011, 31:294-299.
54. Fimiani M., Mazzatenta C., Rubegni P., et al. Idiopathic angiokeratoma corporis diffusum. Clin Exp Dermatol 1997, 22:205-206.
55. Fuller M., Sharp P.C., Rozaklis T., et al. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem 2005, 51:688-694.
56. Gadoth N., Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet 1983, 20:309-312.
57. Garman S.C., Garboczi D.N. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 2004, 337:319-335.
58. Garzuly F., Marodi L., Erdos M., et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 2005, 128:2078-2083.
59. Gasparini G., Sarchi G., Cavicchini S., et al. Angiokeratoma corporis diffusum in a patient with normal enzyme activities and Turner's syndrome. Clin Exp Dermatol 1992, 17:56-59.
60. Gelderman M.P., Schiffmann R., Simak J. Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy. Arterioscler Thromb Vasc Biol 2007, 27:e138-e139.
61. George S., Graham-Brown R.A. Angiokeratoma corporis diffusum in fucosidosis. J R Soc Med 1994, 87:707.
62. Germain D.P. Fabry disease. Orphanet J Rare Dis 2010, 5:30.
63. Germain D.P., Waldek S., Banikazemi M., et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007, 18:1547-1557.
64. Giugliani R., Waldek S., Germain D.P., et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab 2013, 109:86-92.
65. Glass R.B., Astrin K.H., Norton K.I., et al. Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 2004, 28:158-168.
66. Gordon K.E., Ludman M.D., Finley G.A. Successful treatment of painful crises of Fabry disease with low dose morphine. Pediatr Neurol 1995, 12:250-251.
67. Guffon N., Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy - a case series. J Inherit Metab Dis 2004, 27:221-227.
68. Gupta S., Ries M., Kotsopoulos S., et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005, 84:261-268.
69. Han F., Wang P., Li Z., et al. Angiokeratoma corporis diffusum in a patient with Hodgkin lymphoma: a new paraneoplastic skin manifestation?. Br J Dermatol 2013, 168:1351-1353.
70. Hashimoto K., Gross B.G., Lever W.F. Angiokeratoma corporis diffusum (Fabry). Histochemical and electron microscopic studies of the skin. J Invest Dermatol 1965, 44:119.
71. Hauser A.C., Gessl A., Lorenz M., et al. High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit Metab Dis 2005, 28:715-722.
72. Hilz M.J., Brys M., Marthol H., et al. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004, 62:1066-1072.
73. Hoffmann B., Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007, 96:84-86.
74. Hoffmann B., Garcia de Lorenzo A., Mehta A., et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005, 42:247-252.
75. Hopkin R.J., Bissler J., Banikazemi M., et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 2008, 64:550-555.
76. Hornbostel H., Scriba K. Excision of skin in diagnosis of Fabry's angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease. Klin Wochenschr 1953, 31:68-69.
77. Horowitz S.H. The diagnostic workup of patients with neuropathic pain. Med Clin North Am 2007, 91:21-30.
78. Hughes D.A., Elliott P.M., Shah J., et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008, 94:153-158.
79. Inagaki M., Katsumoto T., Nanba E., et al. Lysosomal glycosphingolipid storage in chloroquine-induced alpha- galactosidase-deficient human endothelial cells with transformation by simian virus 40: in vitro model of Fabry disease. Acta Neuropathol 1993, 85:272-279.
80. Inoue T., Hattori K., Ihara K., et al. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013, 58:548-552.
81. Ishii S., Yoshioka H., Mannen K., et al. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta 2004, 1690:250-257.
82. Kalliokoski R.J., Kantola I., Kalliokoski K.K., et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 2006, 29:112-118.
83. Kampmann C., Baehner F.A., Whybra C., et al. The right ventricle in Fabry disease. Acta Paediatr Suppl 2005, 94:15-18. discussion 19-10.
84. Kampmann C., Linhart A., Baehner F., et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008, 130:367-373.
85. Kampmann C., Wiethoff C.M., Whybra C., et al. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 2008, 97:463-469.
86. Kaneski C.R., Moore D.F., Ries M., et al. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology 2006, 67:2045-2047.
87. Kang J.J., Shu L., Park J.L., et al. Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in alpha-galactosidase A. Am J Physiol Gastrointest Liver Physiol 2014, 306:G140-G146.
88. Kawachi Y., Matsu-ura K., Sakuraba H., et al. Angiokeratoma corporis diffusum associated with galactosialidosis. Dermatology 1998, 197:52-54.
89. Kawano M., Takenaka T., Otsuji Y., et al. Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease. Am J Cardiol 2007, 99:261-263.
90. Kaye E.M., Kolodny E.H., Logigian E.L., et al. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988, 23:505-509.
91. Keilmann A. Inner ear function in children with Fabry disease. Acta Paediatr Suppl 2003, 92:31-32. discussion 27.
92. Kint J.A. Fabry's disease: alpha-galactosidase deficiency. Science 1970, 167:1268-1269.
93. Kitagawa T., Suzuki K., Ishige N., et al. Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol 2008, 23:1461-1471.
94. Kleinert J., Dehout F., Schwarting A., et al. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int 2005, 67:1955-1960.
95. Kodama K., Kobayashi H., Abe R., et al. A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with Meniere's syndrome and without mental retardation. Br J Dermatol 2001, 144:363-368.
96. Laaksonen S.M., Roytta M., Jaaskelainen S.K., et al. Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 2008, 119:1365-1372.
97. Lacomis D., Roeske-Anderson L., Mathie L. Neuropathy and Fabry's disease. Muscle Nerve 2005, 31:102-107.
98. Linhart A., Palecek T., Bultas J., et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000, 139:1101-1108.
99. Lobo T., Morgan J., Bjorksten A., et al. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement. Intern Med J 2008, 38:407-414.
100. Low P.A., Opfer-Gehrking T.L. The autonomic laboratory. Am J Electroneurodiagn Technol 1999, 39:65-76.
101. Lowe G.D. Virchow's triad revisited: abnormal flow. Pathophysiol Haemost Thromb 2003, 33:455-457.
102. Lozano F., Garcia-Talavera R., Gomez-Alonso A. An unusual cause of lymphoedema - confirmed by isotopic lymphangiography. Eur J Vasc Surg 1988, 2:129-131.
103. Luciano C.A., Russell J.W., Banerjee T., et al. Physiologic characterization of neuropathy in Fabry disease. Muscle Nerve 2002, 26:622-629.
104. MacDermot J., MacDermot K.D. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001, 429:121-125.
105. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001, 38:750-760.
106. Macrae W.G., Ghosh M., McCulloch C. Corneal changes in Fabry's disease: a clinico-pathologic case report of a heterozygote. Ophthalmic Paediatr Genet 1985, 5:185-190.
107. Maier E.M., Osterrieder S., Whybra C., et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr 2006, 95:30-38.
108. Marshall J., Ashe K.M., Bangari D., et al. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 2010, 5:e15033.
109. Martin L., Sturgess A., Sillence D., et al. Fabry disease in a heterozygote presenting as hand ischaemia and painful acroparaesthesia. Australas J Dermatol 2007, 48:40-42.
110. Massi D., Martinelli F., Battini M.L., et al. Angiokeratoma corporis diffusum (Anderson-Fabry's disease): a case report. J Eur Acad Dermatol Venereol 2000, 14:127-130.
111. Mehta A., Ginsberg L. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005, 94:24-27. discussion 29-10.
112. Mehta A., Ricci R., Widmer U., et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004, 34:236-242.
113. Mehta A., Beck M., Kampmann C., et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 2008, 95:114-115.
114. Meikle P.J., Hopwood J.J., Clague A.E., et al. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
115. Mitsias P., Levine S.R. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996, 40:8-17.
116. Moore D.F., Herscovitch P., Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 2001, 11:303-307.
117. Moore D.F., Scott L.T., Gladwin M.T., et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001, 104:1506-1512.
118. Moore D.F., Altarescu G., Herscovitch P., et al. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002, 2:4.
119. Moore D.F., Altarescu G., Ling G.S., et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002, 33:525-531.
120. Moore D.F., Schiffmann R., Ulug A.M. Elevated CNS average diffusion constant in Fabry disease. Acta Paediatr Suppl 2002, 91:67-68.
121. Moore D.F., Altarescu G., Barker W.C., et al. White matter lesions in Fabry disease occur in "prior" selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003, 62:231-240.
122. Moore D.F., Ye F., Schiffmann R., et al. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003, 24:1096-1101.
123. Moore D.F., Ye F., Brennan M.L., et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 2004, 20:674-683.
124. Moore D.F., Kaneski C.R., Askari H., et al. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007, 257:258-263.
125. Moore D.F., Krokhin O.V., Beavis R.C., et al. Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci U S A 2007, 104:2873-2878.
126. Morel O., Muller C., Jesel L., et al. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 2013, 28:1994-2002.
127. Mougenot P., Lidove O., Caillaud C., et al. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance. Eur J Clin Pharmacol 2008, 64:635-639.
128. Muller C., Caillard S., Jesel L., et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012, 59:777-785.
129. Murray G.J., Anver M.R., Kennedy M.A., et al. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007, 90:307-312.
130. Nakayama Y., Tsumura K., Yamashita N., et al. Dynamic left ventricular arterial pressure gradient and sick sinus syndrome with heterozygous Fabry's disease improved following implantation of a dual chamber pacemaker. Pacing Clin Electrophysiol 1999, 22:1114-1115.
131. Nguyen Dinh Cat A., Escoubet B., Agrapart V., et al. Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease. PLoS One 2012, 7:e33743.
132. Niemann M., Herrmann S., Hu K., et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011, 4:592-601.
133. Niemann M., Rolfs A., Stork S., et al. Gene mutations versus clinically relevant phenotypes: lyso-gb3 defines Fabry disease. Circ Cardiovasc Genet 2014, 7:8-16.
134. Nishino T., Obata Y., Furusu A., et al. Identification of a novel mutation and prevalence study for Fabry disease in Japanese dialysis patients. Ren Fail 2012, 34:566-570.
135. Nistal M., Paniagua R., Picazo M.L. Testicular and epididymal involvement in Fabry's disease. J Pathol 1983, 141:113-124.
136. Ohshima T., Murray G.J., Swaim W.D., et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A 1997, 94:2540-2544.
137. Ohshima T., Schiffmann R., Murray G.J., et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci U S A 1999, 96:6423-6427.
138. Ojo A., Meier-Kriesche H.U., Friedman G., et al. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000, 69:2337-2339.
139. Okeda R., Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology 2008, 28:532-540.
140. Opitz J.M., Stiles F.C., Wise D., et al. The genetics of angiokeratoma corporis diffusum (Fabry's disease), and its linkage with Xg (a) locus. Am J Hum Genet 1965, 17:325-342.
141. Ortiz A., Oliveira J.P., Waldek S., et al. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008, 23:1600-1607.
142. Pacienza N., Yoshimitsu M., Mizue N., et al. Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther 2012, 20:1454-1461.
143. Park J.L., Whitesall S.E., D'Alecy L.G., et al. Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 2008, 35:1156-1163.
144. Pompen A.W., Ruiter M., Wyers H.J. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand 1947, 128:234-255.
145. Ramaswami U. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa. Acta Paediatr Suppl 2008, 97:38-40.
146. Ramaswami U., Whybra C., Parini R., et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006, 95:86-92.
147. Ries M., Mengel E., Kutschke G., et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003, 26:413-414.
148. Ries M., Bettis K.E., Choyke P., et al. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 2004, 66:978-982.
149. Ries M., Gupta S., Moore D.F., et al. Pediatric Fabry disease. Pediatrics 2005, 115:e344-e355.
150. Ries M., Clarke J.T., Whybra C., et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006, 118:924-932.
151. Ries M., Moore D.F., Robinson C.J., et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med 2006, 8:96-101.
152. Ries M., Kim H.J., Zalewski C.K., et al. Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain 2007, 130:143-150.
153. Rodrigues L.G., Ferraz M.J., Rodrigues D., et al. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Neurobiol Dis 2009, 33:48-56.
154. Rolfs A., Bottcher T., Zschiesche M., et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005, 366:1794-1796.
155. Rombach S.M., van den Bogaard B., de Groot E., et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension 2012, 60:998-1005.
156. Rombach S.M., Smid B.E., Linthorst G.E., et al. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis 2014, 37:341-352.
157. Romeo G., Migeon B.R. Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease. Science 1970, 170:180-181.
158. Romeo G., D'Urso M., Pisacane A., et al. Residual activity of alpha-galactosidase A in Fabry's disease. Biochem Genet 1975, 13:615-628.
159. Rowe J.W., Gilliam J.I., Warthin T.A. Intestinal manifestations of Fabry's disease. Ann Intern Med 1974, 81:628-631.
160. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002, 105:1407-1411.
161. Sado D.M., White S.K., Piechnik S.K., et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013, 6:392-398.
162. Schiffmann R. Fabry disease. Pharmacol Therapeut 2009, 122:65-77.
163. Schiffmann R., Kopp J.B., Austin H.A., et al. Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
164. Schiffmann R., Floeter M.K., Dambrosia J.M., et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003, 28:703-710.
165. Schiffmann R., Rapkiewicz A., Abu-Asab M., et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch Nov 2005, 29:1-7.
166. Schiffmann R., Hauer P., Freeman B., et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006, 34:53-56.
167. Schiffmann R., Rapkiewicz A., Abu-Asab M., et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 2006, 448:337-343.
168. Schiffmann R., Ries M., Timmons M., et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006, 21:345-354.
169. Schiffmann R., Askari H., Timmons M., et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007, 18:1576-1583.
170. Schiffmann R., Germain D.P., Castelli J., et al. Phase 2 clinical trials of the pharmacological chaperone AT1001 for the treatment of Fabry disease 2008.
171. Schiffmann R., Warnock D.G., Banikazemi M., et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009, 24:2102-2111.
172. Schiffmann R., Forni S., Swift C., et al. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 2014, 3:e000394.
173. Scott L.J., Griffin J.W., Luciano C., et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999, 52:1249-1254.
174. Senechal M., Germain D.P. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 2003, 63:46-52.
175. Shen Y., Bodary P.F., Vargas F.B., et al. Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 2006, 37:1106-1108.
176. Shen J.S., Meng X.L., Moore D.F., et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008, 95:163-168.
177. Shen J.S., Meng X.L., Wight-Carter M., et al. Blocking hyperactive androgen receptor signaling ameliorates cardiac and renal hypertrophy in Fabry mice. Hum Mol Genet 2015, 24:3181-3191.
178. Sims K., Politei J., Banikazemi M., et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009, 40:788-794.
179. Sirrs S.M., Bichet D.G., Casey R., et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 2014, 111:499-506.
180. Spada M., Pagliardini S., Yasuda M., et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006, 79:31-40.
181. Spinelli L., Pisani A., Sabbatini M., et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004, 66:158-165.
182. Stemper B., Hilz M.J. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol 2003, 250:970-976.
183. Suzuki N., Konohana I., Fukushige T., et al. Beta-mannosidosis with angiokeratoma corporis diffusum. J Dermatol 2004, 31:931-935.
184. Sweeley C.C., Klionsky B.L. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963, 238. PC3148.
185. Tagliavini F., Pietrini V., Gemignani F., et al. Anderson-Fabry's disease: neuropathological and neurochemical investigation. Acta Neuropathol 1982, 56:93-98.
186. Taguchi A., Maruyama H., Nameta M., et al. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis. Biochem J 2013, 456:373-383.
187. Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007, 18:2609-2617.
188. Takanashi J., Barkovich A.J., Dillon W.P., et al. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol 2003, 24:916-921.
189. Takenaka T., Teraguchi H., Yoshida A., et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 2008, 51:50-59.
190. Terryn W., Deschoenmakere G., De Keyser J., et al. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Int J Cardiol 2013, 167:2555-2560.
191. Thompson R.B., Chow K., Khan A., et al. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging 2013, 6:637-645.
192. Tremont-Lukats I.W., Megeff C., Backonja M.M. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 2000, 60:1029-1052.
193. Uceyler N., Homola G.A., Guerrero Gonzalez H., et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One 2014, 9:e87054.
194. van der Tol L., Smid B.E., Poorthuis B.J., et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 2014, 51:1-9.
195. van Mullem P.J., Ruiter M. Fine structure of the skin in angiokeratoma corporis diffusum (Fabry's disease). J Pathol 1970, 101:221-226.
196. Vedder A.C., Linthorst G.E., van Breemen M.J., et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007, 30:68-78.
197. Vedder A.C., Breunig F., Donker-Koopman W.E., et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008, 94:319-325.
198. Vedder A.C., Biro E., Aerts J.M., et al. Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment. Nephrol Dialysis, Transplant 2009, 24:3074-3081.
199. Vibert D., Blaser B., Ozdoba C., et al. Fabry's disease: otoneurologic findings in twelve members of one family. Ann Otol Rhinol Laryngol 2006, 115:412-418.
200. von Scheidt W., Eng C.M., Fitzmaurice T.F., et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991, 324:395-399.
201. Wang R.Y., Lelis A., Mirocha J., et al. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007, 9:34-45.
202. Warnock D.G., Ortiz A., Mauer M., et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012, 27:1042-1049.
203. Weicksel J. Angiomatosis, bzw. Angiokeratosis universalis (eine sehr seltene Haut-und Gafasskrankheit). Dtsch Med Wochenschr 1925, 51:898.
204. Weidemann F., Breunig F., Beer M., et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003, 108:1299-1301.
205. Weidemann F., Breunig F., Beer M., et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005, 26:1221-1227.
206. Whitley C.B., Tsai M.Y., Heger J.J., et al. Amiodarone phenocopy of Fabry's keratopathy. JAMA 1983, 249:2177-2178.
207. Whybra C., Kampmann C., Willers I., et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001, 24:715-724.
208. Wilcox W.R., Banikazemi M., Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004, 75:65-74.
209. Wilcox W.R., Oliveira J.P., Hopkin R.J., et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008, 93:112-128.
210. Wozniak M.A., Kittner S.J., Tuhrim S., et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010, 41:78-81.
211. Wraith J.E., Tylki-Szymanska A., Guffon N., et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 2008, 152:563-570. 570 e561.
212. Yokota M., Koji M., Yotsumoto S. Histopathologic and ultrastructural studies of angiokeratoma corporis diffusum in Kanzaki disease. J Dermatol 1995, 22:10-18.
213. Young-Gqamana B., Brignol N., Chang H.H., et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS One 2013, 8. e57631.
214. Zarate Y.A., Hopkin R.J. Fabry's disease. Lancet 2008, 372:1427-1435.
215. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001, 429:23-37.